Community Practice

Latest News


CME Content


In a multi-national, placebo-controlled, double-blind trial, the selective vitamin D receptor activator paricalcitol (Zemplar, Abbott Laboratories), at doses of 1 µg or 2 µg daily, can reduce albuminuria in patients with type 2 diabetes, who were already being treated with renin-angiotensin-aldosterone system inhibitors.

In research published in the October 1 issue of the American Journal of Cardiology, HealthDay News reported, metformin, either alone or in combination with sulfonylurea, appears to increase 1-year and long-term survival in patients with T2DM and CHF.

Diagnostic testing, narcotics, and questionable treatment modalities appear to be overused for chronic neck pain, while effective treatments such as therapeutic exercise appear to be underused, according to a study in the November issue of Arthritis Care & Research, HealthDay News reported.

Patients are significantly more likely to abandon at the pharmacy prescriptions submitted electronically than those dropped off in person, according to the results of a study appearing in the November 16 issue of Annals of Internal Medicine.

FDA MedWatch

FDA has issued consumer advisories on several products recently, and McNeil Consumer Health Care and Reese Pharmaceutical Co. have issued product recalls.